The global statistics are terrifying. Prostate cancer is the fourth most common cancer in all populations, the second most common cancer among men worldwide, and ranks first in Europe, where a third ...

A 2-step decision analytic model consisting of a decision tree-informed Markov structure was used to estimate lifetime outcomes in older patients with prostate cancer. The P-score reclassifies a ...

Source: Getty Images Despite proven benefits, biomarker tests remain underused in clinical practice. By examining genetic markers from urine or tissue samples, biomarkers provide a more precise ...

Bridging the Gap: The Essential Role of Lymphoma Clinicians in Guiding the Transition From Lymphoma Treatment to Survivorship In the article that accompanies this editorial, Beidler et al 10 presents ...

Despite the clinical utility of biomarker testing in patients with prostate cancer, the tests are infrequently ordered, preventing optimized care. Despite guideline recommendations and the efficacy of ...

Current prostate specific antigen (PSA) testing “may not effectively target testing to those most likely to benefit, raising concerns about overtesting” warn researchers from the University of Oxford ...

New Australian research has highlighted the urgent need for a national framework to guide genetic testing for prostate cancer, with experts warning ...

Prostate cancer screening should be promised in the next Tory manifesto, a former home secretary has said. Sir James Cleverly ...

Results of a cross-sectional survey to explore determinants of health-promoting activities among Hispanic/Latino (H/L) patients (pts) with prostate cancer (PCa) on androgen deprivation therapy (ADT).

According to the World Cancer Research Fund, more than 100,000 men are newly diagnosed with prostate cancer annually in Japan, and a portion of those patients will be diagnosed with or later progress ...